Zhang Lei, Li Xue-Song, Zhou Li-Qun
Department of Urology, Peking University First Hospital, Beijing 100034, China.
Chin Med J (Engl). 2015 May 5;128(9):1232-7. doi: 10.4103/0366-6999.156139.
To review the natural history and growth kinetics of small renal masses (SRMs).
The literature concerning natural history and growth kinetics of SRMs was collected from PubMed published from 1990 to 2014.
We included all the relevant articles on the active surveillance (AS) or delayed treatment for SRMs in English, with no limitation of study design.
SRMs under AS have a slow growth potential in general. The mean linear growth rate is 0.33 cm/year, the mean volumetric growth rate is 9.48 cm 3 /year. The rate of metastasis during AS is below 2%. Some factors are associated with the growth rate of SRMs, including tumor grade, histological subtype, initial tumor size, age, radiographic characteristics, and molecular markers. No definite predictor of growth rate of SRMs is defined at present. SRMs with high tumor grade and the subtype of clear cell renal cell carcinoma may have aggressive growth potential.
AS is a reasonable choice for elderly patients with SRMs, who are at high risk from surgery. Progression during observation is the biggest concern while performing AS. There is no definite predictor of progression for SRMs under AS. Percutaneous renal biopsy providing immunohistological and genic biomarkers may improve the understanding of natural history of SRMs.
回顾小肾肿块(SRMs)的自然病程和生长动力学。
关于SRMs自然病程和生长动力学的文献从1990年至2014年发表在PubMed上的文献中收集。
我们纳入了所有关于SRMs主动监测(AS)或延迟治疗的英文相关文章,研究设计无限制。
接受AS的SRMs总体生长潜力缓慢。平均线性生长率为0.33厘米/年,平均体积生长率为9.48立方厘米/年。AS期间转移率低于2%。一些因素与SRMs的生长率相关,包括肿瘤分级、组织学亚型、初始肿瘤大小、年龄、影像学特征和分子标志物。目前尚未确定SRMs生长率的明确预测指标。高肿瘤分级的SRMs和透明细胞肾细胞癌亚型可能具有侵袭性生长潜力。
对于手术风险高的老年SRMs患者,AS是一种合理的选择。在进行AS时,观察期间的进展是最大的关注点。接受AS的SRMs尚无明确的进展预测指标。提供免疫组织学和基因生物标志物的经皮肾活检可能会提高对SRMs自然病程的认识。